Cayman ARQ 092

ARQ 092 is an allosteric, orally bioavailable, pan-Akt inhibitor (IC₅₀s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively).¹ It is selective for Akt isoforms over a panel of 303 other kinases.¹ ARQ 092 binds inactive Akt and prevents membrane localization and full Akt activation.^1,2 It also directly inhibits the membrane-associated active form of Akt, preventing phosphorylation of downstream targets.^1,2 ARQ 092 inhibits the proliferation of a wide range of cancer cells in vitro, inhibits the mutated Akt form found in Proteus syndrome, and attenuates heterotypic cell-cell interactions in a mouse model of sickle cell disease.^1,2,3,4

WARNING This product is not for human or veterinary use.